Jay Sandberg, DO
Internal Medicine · Troy, MINPI 1548293483
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $14,952 of the $24,010 with a category attached, or 62.3%. 49 manufacturers reported payments, led by Novo Nordisk at 30.7% of the total. Reporting peaked in 2024 at $5,203 and has fallen 62.1% since, to $1,969 in 2025. Among internal medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 933 payments — averaging $25.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$7K
- Amgen$5K
- AstraZeneca$2K
- Lilly USA, LLC$1K
- Pfizer$974
- AbbVie$820
- plus $7K from 43 others
Across 631 payments — averaging $13,081 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$3M
- Modernatx, Inc.$1.4M
- Sanofi US Services Inc.$1.1M
- Janssen Research & Development, LLC$604K
- Genentech, Inc.$438K
- GSK$379K
- plus $1.3M from 19 others
What the payments were for
- Consulting fees$7,83633%
- Speaking & faculty fees$440%
- Travel & lodging$8754%
- Food & beverage$14,95262%
- Education$3031%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,010 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 110 | $143,414 |
| EliquisApixaban | 106 | $129,099 |
| FarxigaDapagliflozin Propanediol | 114 | $106,017 |
| MounjaroTirzepatide | 80 | $99,987 |
| JardianceEmpagliflozin | 76 | $97,985 |
| XareltoRivaroxaban | 72 | $81,138 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $77,949 |
| TrulicityDulaglutide | 34 | $54,998 |
| MyrbetriqMirabegron | 73 | $49,983 |
| EntrestoSacubitril/Valsartan | 55 | $48,512 |
| KerendiaFinerenone | 45 | $45,702 |
| RybelsusSemaglutide | 30 | $39,584 |
| XifaxanRifaximin | 11 | $35,366 |
| TrintellixVortioxetine Hydrobromide | 28 | $28,576 |
| LinzessLinaclotide | 38 | $27,127 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy | $7,366 | $200,836154 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,131 | $154,985114 claims |
| PfizerEliquis | $974 | $129,099106 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $336 | $110,11387 claims |
| AstraZenecaFarxiga | $1,779 | $106,017114 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $520 | $91,41484 claims |
| Johnson & JohnsonXarelto | $454 | $81,13872 claims |
| Astellas Pharma US IncMyrbetriq | $534 | $49,98373 claims |
| NovartisEntresto | $421 | $48,51255 claims |
| BayerKerendia | $80 | $45,70245 claims |
| AbbVieLinzess, Vraylar | $820 | $44,50251 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $501 | $35,36611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Troy
- John CaladoTroy$198K
- Michael DoyleTroy$38K
- Terry SmithAnn Arbor$2.3M
- Michael ValituttoKalamazoo$1.8M
- Ulka VaishampayanAnn Arbor$996K
- Tina AbrahamPontiac$834K
- Steven KatzmanLivonia$715K
- Adam FormanSouthfield$453K
- Saroj NeupaneDetroit$373K
- James BazziDearborn Heights$368K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.